| |
•
•
•
|
| |
Proud sponsor of:
|
|
| |
| November 3, 2008 | MediciNova to Present at the Rodman and Renshaw 10th Annual Healthcare Conference | | SAN DIEGO, Calif. – November 3, 2008 – MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Trading Symbol: MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number: 4875), today announced that Shintaro Asako, Chief Financial Officer of MediciNova, will present a company overview at the Rodman and Renshaw 10th Annual Healthcare Conference on Monday, November 10, 2008 at 11:35 a.m. Eastern time. The conference is being held at The Palace Hotel in New York City.
A live webcast of the presentation can be accessed through MediciNova’s Investor Relations website at http://investors.medicinova.com. An archived version of the presentation will be available for approximately 60 days following the event.
About MediciNova
MediciNova, Inc. is a publicly-traded biopharmaceutical company focused on acquiring and developing novel, small-molecule therapeutics for the treatment of diseases with unmet need with a specific focus on the U.S. market. Through strategic alliances primarily with Japanese pharmaceutical companies, MediciNova holds rights to a diversified portfolio of clinical and preclinical product candidates, each of which MediciNova believes has a well-characterized and differentiated therapeutic profile, attractive commercial potential and patent assets having claims of commercially adequate scope. MediciNova’s pipeline includes six clinical-stage compounds for the treatment of status asthmaticus, multiple sclerosis, asthma, interstitial cystitis, solid tumor cancers, Generalized Anxiety Disorder, preterm labor and urinary incontinence and two preclinical-stage compounds for the treatment of thrombotic disorders. MediciNova’s current strategy is to focus its resources on the development and commercialization of two prioritized assets in its development pipeline: MN-221 for the treatment of status asthmaticus, an acute, severe asthma attack, and MN-166 for the treatment of multiple sclerosis. MediciNova will seek to monetize its other product candidates at key value inflection points. For more information on MediciNova, Inc., please visit www.medicinova.com.
CONTACT:
Shintaro Asako
Chief Financial Officer
Phone: 858-373-1500
E-mail: info@medicinova.com
Rhonda Chiger
RX Communications, LLC
Phone : (917) 322-2569
E-mail : rchiger@rxir.com
| | November 4, 2008 | Alexion to Present at Investor Conferences | | Cheshire, CT, November 4, 2008 -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that Leonard Bell, M.D., Chief Executive Officer of Alexion Pharmaceuticals, will present at two upcoming investor conferences, one sponsored by Deutsche Bank and the other by Credit Suisse.
Dr. Bell will present at Deutsche Bank’s DB-Biotech Boston Confab Conference in Boston at 1:05 p.m. Eastern Time, on Tuesday, November 11, 2008. Dr. Bell will also present at the 2008 Credit Suisse Healthcare Conference in Phoenix at 8:00 a.m. local time (10:00 a.m. Eastern Time), on Thursday, November 13, 2008.
An audio webcast of Dr. Bell’s remarks from both conferences will be available live on Alexion’s web site at www.alexionpharm.com. An archived version of the remarks will also be available on the web site for a limited time following the conference.
[ALXN-G]
Contacts:
Alexion Pharmaceuticals, Inc.
Irving Adler
Sr. Director, Corporate
Communications
(203) 271-8210
Makovsky + Company
Mark Marmur (Media)
(212) 508-9670
Rx Communications
Rhonda Chiger (Investors)
(917) 322-2569
| | November 5, 2008 | Living Cell Technologies to Present at Rodman & Renshaw 10th Annual Healthcare Conference | | November 5, 2008 – Sydney, Australia, Auckland, New Zealand and Boulder, USA – Living Cell Technologies Limited (ASX:LCT; OTCQX:LVCLY) today announced that Dr. Robert Caspari, Chief Executive Officer of Living Cell Technologies, will present at the Rodman & Renshaw 10th Annual Healthcare Conference in New York City on Wednesday, November 12, 2008 at 2:50 p.m., Eastern Time.
A webcast of Dr. Caspari’s remarks will be available live. You can access the webcast at: www.lctglobal.com. An archived version of the remarks will also be available through the Company’s web site for a limited time following the conference.
About Living Cell Technologies: www.lctglobal.com
Living Cell is developing cell-based products to treat life threatening human diseases. The Company owns a biocertified pig herd that it uses as a source of cells for treating diabetes and neurological disorders. For patients with Type 1 diabetes, the Company transplants microencapsulated islet cells so that near-normal blood glucose levels may be achieved without the need for administration of insulin or at significantly reduced levels. The company entered clinical trials for its diabetes product in 2007. For the treatment of Huntington’s disease and other neurological disorders, the company transplants microencapsulated choroid plexus cells that deliver beneficial proteins and neurotrophic factors to the brain. Living Cell’s technology enables healthy living cells to be injected into patients to replace or repair damaged tissue without requiring the use of immunosuppressive drugs to prevent rejection. Living Cell also offers medical-grade porcine-derived products for the repair and replacement of damaged tissues, as well as for research and other purposes.
LCT Disclaimer
This document contains certain forward-looking statements, relating to LCT’s business, which can be identified by the use of forward-looking terminology such as “promising,” “plans,” “anticipated,” “will”, “project”, “believe”, “forecast”, “expected”, “estimated”, “targeting”, “aiming”, “set to,” “potential,” “seeking to,” “goal,” “could provide,” “intends,” “is being developed,” “could be,” “on track,” or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA’s and other health authorities’ requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management’s expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. LCT is providing this information as of October 23, 2008, and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.
# # #
Contacts:
Dr Robert Caspari
Chief Executive Officer
Mob: +1 303-859-5718
Tel:+1 303-442-2519
rcaspari@lctglobal.com
Dr. Bob Elliott
Medical Director
Mob: +64 27 292 4177
Tel:+64 9 276 2690
relliott@lctglobal.com
Dr. Paul Tan
Chief Operating Officer
Mob: 0402 716 984 (AUS)
Mob: 021 608 784 (NZ)
Tel: +64 9 270 7941
Melody Carey
Investor and Media Relations (US)
Tel: +1 917-322-2571
mcarey@rxir.com
|
|
|
|
|
|
